📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-13 15:33
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Vivo Bio Tech Reports Fire Accident at Telangana Research Facility; Damage Under Assessment
Vivo Bio Tech Ltd reported a fire incident in the early hours of October 13, 2026, at its research facility located in Gajwel, Siddipet District, Telangana. The fire caused extensive damage to laboratory rooms, scientific equipment, plant and machinery, as well as sponsor test items, pathology specimens, and the PICO facility. No injuries or casualties were reported, and the company stated that assets are adequately insured, with insurance claim processes underway. With TTM revenue standing at Rs 55 Cr and TTM PAT at -Rs 3 Cr, any operational disruption from sample destruction and lab downtime could pressure upcoming quarters.
Confidence: HIGH
What changedA fire accident destroyed laboratory equipment, sponsor test samples, and pathology specimens at Vivo Bio Tech's Telangana research facility on October 13, 2026.
Why it mattersThe destruction of sponsor samples and laboratory infrastructure could halt ongoing research studies, delay contract execution, and hurt cash flows for a small-cap firm (mcap Rs 37 Cr) already facing negative TTM net profit (-Rs 3 Cr).
Incident Date: October 13, 2026Expected Loss Quantum: not disclosedFacility Location: Survey No. 349/A, Pregnapur, Gajwel, TelanganaTTM Revenue Context: Rs 55 Cr
📅 Short termExpect negative sentiment as operations at the research facility face disruption, with potential revenue loss and client friction due to destroyed sponsor study samples.
📈 Long termDepending on insurance claim recovery speed and rebuilding timelines, the company could face prolonged business delays and customer attrition in contract research.
⚠ Risk flags
- Loss of sponsor study samples and client trust
- Operational halt at affected laboratories
- Insurance recovery delays or under-recovery
Key Highlights
Fire broke out in early hours of October 13, 2026, at research facility in Survey No. 349/A, Gajwel, Telangana
Damage reported to laboratory rooms, scientific equipment, plant & machinery, Pathology Laboratory, and PICO facility
Valuable sponsor test items, samples for ongoing and future studies, and pathology specimens were destroyed
Zero casualties or injuries reported; assets are stated to be adequately covered by insurance
Expected quantum of financial loss and operational disruption are currently under assessment
👀 What to Watch
Track subsequent exchange filings for the quantified loss, insurance settlement timelines, and any operational downtime impact on quarterly revenue and sponsor contracts.
Vivo Bio Tech Q1 Revenue up 14% YoY to ₹14.28 Cr; Net Profit drops 86% to ₹0.19 Cr
Vivo Bio Tech reported a 14.1% YoY increase in consolidated revenue to ₹1,427.97 Lacs for the quarter ended June 30, 2026. However, net profit plummeted by 86% YoY to ₹18.76 Lacs, down from ₹133.71 Lacs in the previous year's corresponding quarter. This sharp decline is primarily attributed to a 47.7% surge in employee costs and a 33.6% increase in depreciation expenses. Consequently, the net profit margin has compressed significantly to approximately 1.3%.
Confidence: HIGH
What changedThe company has moved from a double-digit net margin (10.7%) in Q1 FY26 to a near-breakeven performance (1.3%) in Q1 FY27 despite growing its top line.
Why it mattersThe results indicate that operational overheads (staff and assets) are growing much faster than revenue, severely impacting the bottom line and investor returns, which have already seen a 34.4% decline over the last 12 months.
Consolidated Revenue (Q1 FY27): ₹1,427.97 LacsNet Profit (Q1 FY27): ₹18.76 LacsYoY Revenue Growth: 14.1%YoY Net Profit Growth: -86.0%Employee Cost Increase: 47.7%
📅 Short termThe stock may face downward pressure as the market reacts to the substantial drop in profitability and margin compression.
📈 Long termThe long-term outlook depends on the company's ability to leverage its increased cost base into higher revenue; currently, the high fixed costs pose a risk to sustainable profitability.
⚠ Risk flags
- Significant margin compression
- High fixed cost growth (Employee & Depreciation)
- Negative 12-month price momentum (-34.4%)
Key Highlights
Consolidated Revenue from operations increased 14.1% YoY to ₹1,427.97 Lacs.
Net Profit after tax fell 86% YoY to ₹18.76 Lacs from ₹133.71 Lacs.
Employee costs rose significantly by 47.7% YoY to ₹472.98 Lacs.
Depreciation and amortization expenses increased 33.6% YoY to ₹353.17 Lacs.
Basic and Diluted EPS dropped to ₹0.08 from ₹0.74 in the year-ago quarter.
👀 What to Watch
Investors should monitor whether the sharp rise in employee and depreciation costs is tied to new capacity that will scale revenue in coming quarters, or if it represents a permanent structural decline in margins.
Vivo Bio Tech Q1 PAT Drops 86% YoY to ₹18.76 Lacs Despite 14% Revenue Growth
Vivo Bio Tech reported a consolidated revenue of ₹1,427.97 Lacs for Q1 FY27, representing a 14.1% increase from ₹1,251.16 Lacs in the year-ago period. However, Net Profit plummeted by 86% YoY to ₹18.76 Lacs, down from ₹133.71 Lacs, as operating expenses surged. The profit decline was driven by a 47.7% rise in employee costs and a 33.6% increase in depreciation, significantly compressing margins. Consequently, the Basic EPS fell sharply to ₹0.08 from ₹0.74 YoY.
Confidence: HIGH
What changedThe company experienced a severe margin squeeze in Q1 FY27, where a 14% revenue increase was overshadowed by a 25% increase in total expenses.
Why it mattersThe sharp rise in fixed costs like depreciation and employee expenses suggests the company has expanded its cost base, but current revenue levels are insufficient to maintain previous profit margins.
Consolidated Revenue (Q1 FY27): ₹1,427.97 LacsConsolidated PAT (Q1 FY27): ₹18.76 LacsYoY Revenue Growth: 14.1%YoY PAT Growth: -85.97%Employee Cost (Q1 FY27): ₹472.98 Lacs
📅 Short termThe stock is likely to react negatively in the short term due to the substantial decline in profitability and EPS.
📈 Long termThe long-term outlook depends on the company's ability to scale revenue to absorb the higher depreciation and employee overheads seen this quarter.
⚠ Risk flags
- Significant margin compression
- Sharp rise in fixed operating costs
- High depreciation relative to net profit
Key Highlights
Consolidated Revenue from operations grew 14.1% YoY to ₹1,427.97 Lacs
Net Profit After Tax (PAT) declined 86% YoY to ₹18.76 Lacs
Employee costs increased significantly by 47.7% YoY to ₹472.98 Lacs
Depreciation and amortization expenses rose 33.6% YoY to ₹353.17 Lacs
Profit Before Tax (PBT) fell to ₹33.86 Lacs compared to ₹147.99 Lacs in Q1 FY26
👀 What to Watch
Investors should monitor the company's operating leverage and whether the increased employee and depreciation costs (likely from recent capacity additions) will be offset by higher revenue in subsequent quarters.
